PR Newswire BiotechOriginal article
Glytec Receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an Insulin Management Technology for Hospitalized Newborns and Infants
RegulatoryGlucommander PediatricsPositive
AI Analysis
Summary
Glytec's Glucommander Pediatrics received FDA Breakthrough Device Designation for insulin dosing management in hospitalized newborns and infants, a population without prior FDA-cleared insulin dosing software solutions.
Outcome Details
FDA Breakthrough Device Designation granted for Glucommander Pediatrics, covering a population for which no insulin dosing recommendation software has been FDA-cleared
Importance:7/10
Sentiment:
0.80
FDA Breakthrough DesignationMedical DeviceInsulin ManagementPediatricsRegulatory
Related Companies
Read the original article
Published by PR Newswire Biotech on September 24, 2026 1:06 PM